Is this your firm? Get featured or correct your listing →
At a glance
TCGX appears in 2 funding rounds tracked by ValueAddVC since 2026, leading 2. Its most recent tracked deal was TriGemX Bio's $94M round (Oct 11, 2026).
Recent changes
- Oct 11, 2026Oct 11, 2026Invested in TriGemX Bio ($94M) Pulse 2.0
- Aug 11, 2026Aug 11, 2026Invested in Vaderis Therapeutics (Series B, $152.5M) PR Newswire
Portfolio
3 totalRecent Investment Activity
2Track record: led 2 and participated in 0 of 2 tracked venture rounds · 2 in the last 12 months · led 1 Series B
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 11, 2026 | TriGemX Bio | funding round | Led | $94M | — | TCGXLeadunverifiedColumn Group | Pulse story |
| Aug 11, 2026 | Vaderis Therapeutics | Series B | Led | $152.5M | — | Goldman Sachs AlternativesLeadTCGXLead | Pulse story |
Co-Investors
9Similar Firms
overlapping sector, stage or regionLatest Pulse
TCGX FAQ
What companies has TCGX invested in?
TCGX's portfolio includes TriGemX Bio, Vaderis Therapeutics, Ollin Biosciences.
Who does TCGX co-invest with most?
In the rounds Value Add tracks, TCGX most often invests alongside Andreessen Horowitz (1 shared deal), ARCH Venture Partners (1 shared deal), Blackstone Multi-Asset Investing (1 shared deal), Commodore Capital (1 shared deal), Goldman Sachs Alternatives (1 shared deal).
Sources & methodologyshow
- PR Newswireprimary source1 fact
- Pulse 2.0Value Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.